Eisai's Q3 sales climb, with Fycompa, Humira, Lenvima making up for returned Aloxi rights in US

Headline results for the third quarter:


157.1 billion yen ($1.4 billion)

Versus 154.9 billion yen ($1.4 billion)


7.4 billion yen ($67 million)

Versus 10.3 billion yen ($94 million)

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

Eisai attributed growth to higher sales of Lenvima, following its approval for the treatment of hepatocellular carcinoma in the US, EU and China, as well as increased revenue from Humira and Fycompa. The company noted that the products absorbed the impact of drug pricing revision in Japan, along with the return of marketing rights for Aloxi in the US.

Other results:

  • Lenvima: 18.9 billion yen ($172 million), up from 8.7 billion yen ($79 million) in the prior year
  • Halaven: 10.9 billion yen ($99 million), up from 10.4 billion yen ($95 million)
  • Fycompa: 5.1 billion yen ($46 million), up from 3.9 billion yen ($35 million)
  • Belviq: 2 billion yen ($18 million), up from 1.1 billion yen ($10 million)
  • Aloxi: 200 million yen ($1.8 million), down from 10.7 billion yen ($97 million)

Looking ahead:

Eisai reaffirmed its annual guidance, with revenue of 636.5 billion yen ($5.8 billion), representing 6.1-percent growth over the 2017 fiscal year, as well as 16.7-percent growth in profit to 60.5 billion yen ($550 million).

Pipeline update:

Eisai disclosed that will to initiate a single Phase III confirmatory study of BAN2401 in early Alzheimer's disease patients by the end of March following feedback from regulators in the US, EU and Japan.

To read more Top Story articles, click here.